Myeloma Steering Committee
The NCI Myeloma Steering Committee (MYSC) was established in 2009.
The MYSC follows an efficient, cost-effective, science-driven, and transparent process to identify and promote the "Best Science" in clinical research on myeloma and related diseases by addressing the design and prioritization of phase 3 trials and large phase 2 studies.
Clinical Trials Planning Meetings (CTPMs)
- Strategies and Planning Working Group – May 2011
CCCT Contact: Lawrence Baizer, Ph.D.